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226 Abstract 
27 The purpose of this study was to investigate androgen production and the role of insulin and LH in its 
28 regulation in subcutaneous adipose tissue (SAT) of women with polycystic ovarian syndrome (PCOS). 
29 Protein and mRNA expression of androgen synthesis enzymes (Cytochrome P450 17A1 [CYP17A1] and 
30 Aldo-keto reductase 1C3 [AKR1C3]) were measured in SAT biopsies from women with PCOS, diagnosed 
31 according to the Rotterdam criteria (n=15) and healthy controls (n=15). Cultured mature adipocytes 
32 (differentiated from SAT biopsies) were treated with insulin ± phosphoinositol-3-kinase inhibitor 
33 (LY294002) or LH ± insulin. CYP17A1 and AKR1C3 mRNA expression and testosterone concentrations 
34 were measured in treated and untreated adipocyte cultures. AKR1C3 mRNA was significantly (P<0.001) 
35 greater in PCOS versus non-PCOS SAT, but CYP17A1 was not significantly different between the two 
36 groups. AKR1C3 and CYP17A1 protein expression was not significantly different in PCOS versus non-
37 PCOS SAT. In untreated adipocyte cultures, CYP17A1, AKR1C3 and testosterone levels were significantly 
38 higher in the PCOS versus the non-PCOS groups. Addition of insulin increased AKR1C3 mRNA and 
39 testosterone levels, but not CYP17A1 mRNA in non-PCOS with no effect on PCOS adipocytes. The 
40 stimulatory effects of insulin were not inhibited by LY294002. Addition of LH increased CYP17A1, 
41 AKR1C3 and testosterone in non-PCOS adipocytes with no effect in PCOS adipocytes. In conclusion, 
42 SAT of women with PCOS produces excess androgen, which may contribute to PCOS-related 
43 hyperandrogenaemia. This SAT androgen excess is independent of obesity and is not directly stimulated 
44 by inulin or LH. 
45
46  
47
48
49
50
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351 Introduction 
52 Polycystic ovarian syndrome (PCOS) is the most common ovarian endocrinopathy with a prevalence of 6–
53 10% based on National Institutes of Health (NIH) criteria (Fauser et al. 2012) and 17% according to 
54 Rotterdam consensus criteria (Lauritsen et al. 2014). It accounts for 83% of anovulatory infertility (Kousta 
55 et al. 1999) and 89% of hyperandrogenism (Elhassan et al. 2018). It is characterized by a varied 
56 combination of clinical (anovulation and hyperandrogenism), biochemical (excess serum luteinizing 
57 hormone (LH) and androgen concentrations) and ovarian morphological (polycystic ovaries) features. 
58 PCOS is well-known to negatively affect the quality of life and psychological wellbeing of women (Li Y 
59 et al. 2011) and is associated with significant long-term metabolic and cardiovascular morbidities (Fauser 
60 et al. 2012).
61 Despite its high prevalence, the underlying mechanisms of PCOS remain largely uncertain. It is well 
62 established that androgen excess plays a central role in PCOS pathogenesis. Current evidence suggests 
63 three main cellular sources for this androgen excess including ovarian theca cells (Gilling-Smith et al. 
64 2005), adrenal cortical cells (Kumar et al. 2005) and adipocytes (Rosenfield et al. 2011; O'Reilly et al. 
65 2017). Aldo-keto reductase 1C3 (AKR1C3), also known as 17β-hydroxysteroid dehydrogenase type 5 (17β-
66 HSD5) has been reported as the predominant androgen biosynthesis enzyme in adipose tissue that converts 
67 androstenedione to testosterone (Quinkler et al. 2004). Recent research has shown evidence of increased 
68 SAT AKR1C3 mRNA expression (Wang et al. 2012; O'Reilly et al. 2017) and increased intra-adipose 
69 concentrations of testosterone in women with PCOS (O'Reilly et al. 2017). AKR1C3 expression and 
70 activity in omental adipose tissue were found to correlate positively with adiposity (Blouin et al. 2005). 
71 Furthermore, simple obesity has been associated with increased androgen production in reproductive age 
72 women (Samojlik et al. 1984; Kirschner et al. 1990). Therefore, it remains to be determined whether 
73 increased adipose tissue AKR1C3 expression in PCOS women is independent of obesity.    
74 Although, hyperinsulinaemia (due to insulin resistance) and hyperandrogenaemia are closely linked and 
75 positively correlated in PCOS women, the exact interaction between them remains unclear. Recently, 
76 O’Reilly and co-workers reported that insulin significantly increased AKR1C3 mRNA expression in 
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477 differentiated subcutaneous adipocytes and increased testosterone generation in cell media from cultured 
78 subcutaneous adipocytes from non-PCOS women (O'Reilly et al. 2017). Currently, there are no data on 
79 insulin actions in adipose tissue of PCOS women. Furthermore, there are no data on the mechanisms of 
80 insulin-mediated effects on androgen production in adipocytes of women with or without PCOS. 
81 Currently, there are only limited and conflicting data on the mechanisms of insulin actions in theca cells. 
82 One study involving theca cells from normal ovaries has suggested phosphatidylinositol-3-kinase (PI-3k) 
83 as a possible insulin signaling mediator for insulin stimulatory effects on CYP17 (Munir et al. 2004). On 
84 the other hand, the insulin-mediated increase in steroidogenesis in granulosa lutein cells of normal ovaries 
85 was independent of the PI-3K pathway (Poretsky et al. 2001). Therefore, the role of the PI-3K pathway in 
86 normal and polycystic ovaries remains uncertain. Another area of uncertainty is whether insulin alone is 
87 capable of stimulating androgen synthesis or requires LH-induced cAMP activation. Currently there are 
88 only few and conflicting data on the interaction between insulin and LH in ovarian tissue (Munir et al. 
89 2004, Nestler et al.1998) with no data for adipose tissue.  
90 Based on the above, we hypothesized that hyperinsulinaemia with or without excess LH in women with 
91 PCOS could augment androgen production in peripheral adipose tissue through a mechanism involving 
92 the PI-3K insulin signaling pathway. This hypothesis has never previously been tested in PCOS. The aim 
93 of this in-vitro study was to measure expression of the main androgen synthesizing enzymes (AKR1C3 
94 and Cytochrome P450 17A1 (CYP17A1), also called 17α-hydroxylase, 17,20-lyase) in SAT from women 
95 with and without PCOS. We also measured expression of these enzymes and testosterone concentrations 
96 in mature adipocyte cultures (prepared from SAT) incubated with different concentrations of insulin ± PI-
97 3K inhibitor (LY294002) or LH ± insulin.
98
99 Methods
100 This study was approved by the Derbyshire Ethics Committee (Ref: 09/H0401/27) and all participants 
101 gave written informed consent. 
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5102 Subjects 
103 The study included a group of PCOS women and a control group of age and BMI-matched healthy women 
104 who were scheduled to undergo elective gynaecological surgery at Royal Derby Hospital. All participants 
105 were of reproductive age (20-45) with a BMI of 20-35k/m2.   
106 PCOS was diagnosed according to Rotterdam consensus criteria, by at least two of the following three 
107 features: 1) oligo-/anovulation, 2) clinical and/or biochemical hyperandrogenaemia (testosterone≥2.5 
108 nmol/l or FAI≥5%), or 3) sonographic appearance of polycystic ovaries (The Rotterdam ESHRE/ASRM-
109 Sponsored PCOS consensus workshop group 2004).
110 Healthy controls (non-PCOS) included women with regular menstrual cycles, normal serum testosterone 
111 levels <2.5 nmol/l and normal FAI<5%. 
112 Exclusion criteria were endocrine or metabolic disorders e.g. thyroid disease, diabetes or 
113 hyperprolactinaemia, concurrent hormonal therapy e.g. contraceptive pill, anti-androgenic medication and 
114 corticosteroids or any weight loss medicines. Women unable to provide written informed consent were 
115 excluded. 
116 Adipose tissue biopsies
117 Approximately 5g of subcutaneous adipose tissue (SAT) samples were obtained from abdominal incisions 
118 during elective gynaecological procedures including ovarian drilling, salpingectomy, myomectomy and 
119 diagnostic laparoscopy. The biopsy was divided into two parts, one immediately snap frozen and stored at 
120 -80°C until use for expression analyses. The second part was transferred into a sterile container containing 
121 Hanks’ balanced salt solution (HBSS) for primary cell culture on the same day.
122 SAT primary cell culture
123 These were prepared as described in our previous publication (Cadagan et al. 2014). Briefly, SAT biopsies 
124 were cut into small pieces and enzymatically dispersed using collagenase (1mg/ml) prepared in divalent 
125 cation-free HBSS. The preparation was incubated at 37°C for no more than 60 minutes then filtered 
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6126 through a 250μm nylon mesh. This resulted in a solution with two phases with the lower phase containing 
127 the stromal vascular function which includes preadipocytes. The lower phase was removed and 
128 centrifuged at 1000rpm for 5 minutes. The pellet (containing preadipocytes) was collected and 
129 resuspended in high glucose (4500mg/L) Dulbecco’s minimum essential medium (DMEM) supplemented 
130 with 10% fetal bovine serum and 1% penicillin/streptomycin for culturing in a separate T25flask. Cells 
131 were maintained at 37°C in an air/5% CO2 environment, until confluent (4-6 days). 
132 To initiate in-vitro differentiation into mature adipocytes, preadipocytes were seeded at a density of 3x105 
133 cells/ml in a 24-well plate. Differentiation was induced (Day 0) with the addition of a hormone cocktail 
134 (denoted IDM) comprising 50nM insulin, 0.25mM 3-isobutyl-1-methylxanthine (IBMX) and 100nM 
135 dexamethasone. After 2 days, IDM was replaced with maintenance differentiation medium (MDM), 
136 similar to IDM but without IBMX.  Triacylglycerol droplets became visible on Day 5 and cells were fully 
137 differentiated into adipocytes on Day 14. For negative controls, cells were maintained in DMEM 
138 containing FBS alone.
139 In-vitro differentiated mature adipocytes were kept for 24hrs in serum-free DMEM to prepare for the 
140 experiments. The cultures were then either left untreated (controls) or incubated for 72 hours with insulin 
141 (1, 10, 100nM) ± LY294002 (1g/ml) or LH (10nmol/ml) ± insulin (1, 10, 100nM). The culture media 
142 were then removed from each well and testosterone concentrations were measured by a competitive 
143 ELISA using acetylcholinesterase (AChE) according to the manufacturer’s instructions (Cayman 
144 Chemicals, Michigan, USA). This assay is based on the competition between testosterone and the 
145 testosterone AChE tracer for the antiserum binding sites and is inversely proportional to the concentration 
146 of antigen in the well. The assay was carried out by the addition of 50l of testosterone standards (3.9-
147 500pg/ml), cell culture supernatants, and media blanks, to precoated wells in a 96-well plate. Also 
148 included were wells for total activity and non-specific binding and all were carried out in duplicate. The 
149 plate was then incubated at 37oC for two hours, after which the wells were emptied and washed 5 times. 
150 Then, Ellman’s reagent (200l) was added to each well and the plate incubated (60-90 minutes) in the 
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7151 dark, with shaking before reading at 405nm. Cells remaining in wells were washed, harvested and stored 
152 at -800C for qRT-PCR.  
153 RNA isolation and qRT-PCR
154 Frozen SAT biopsies (100-120mg) were homogenised (Janke and Kunkel, IKA Labortechnik, Germany) 
155 in TRI Reagent (Sigma Aldrich, Dorset, UK). The homogenate was then transferred to an Eppendorf tube 
156 and centrifuged at 12,000g for 15 minutes. The resulting fat layer overlying the homogenate was removed 
157 to avoid any carryover. Chloroform was then added to the homogenate (0.2ml of chloroform for every 1ml 
158 TRI Reagent), mixed thoroughly by manual shaking for 15 seconds, incubated at room temperature for 3 
159 minutes then centrifuged for 15 minutes at 12,000g at 4°C. The resulting upper aqueous layer containing 
160 RNA was transferred to a new RNAse-free 1.5ml microcentrifuge tube. Total RNA was precipitated with 
161 isopropyl alcohol followed by incubation at room temperature for 10 minutes then centrifugation at 
162 12,000g for 10 minutes at 4°C. The RNA pellet produced was washed with 75% ethanol, centrifuged at 
163 7,500g for 5 minutes at 4 °C before dissolving the RNA pellet in RNase free water. 
164 Total RNA from cultured mature adipocytes was extracted as described above except that TRI Reagent 
165 was added at 1ml for every 10cm2 of the culture plate and cells lysed directly.
166 Reverse transcription was carried out using the High-Capacity cDNA Reverse Transcription Kit with 
167 RNAse inhibitor (Applied Biosystems, Vilnius, Lithuania); 1200ng of total RNA was used to produce 
168 20l of cDNA. Reverse transcription was performed at 250C for 10 minutes, 370C for 2 hours, and 850C 
169 for 5 minutes. Each reaction was performed in duplicate: one containing the reverse transcriptase (+RT) 
170 and other one without RT (RT) in which reverse transcriptase was substituted with water. 
171 qRT-PCR for CYP17A1 (17,20 alpha hydroxylase) and AKR1C3, (17B HSD5) was performed alongside 
172 three selected reference genes (GAPDH, ACTB and LRP10). The assay was performed using 2l cDNA 
173 template and 18µl TaqMan Universal PCR Master Mix (Applied Biosystems, California, USA) containing 
174 the specific TaqMan expression assay for the selected gene (Applied Biosystems, California, USA). Each 
175 reaction was carried out in triplicate on +RT samples, and RT samples as well as a no template control 
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8176 (NCT). qPCR was carried out on a Chromo 4 (BioRad, UK) utilising an initial denaturation step at 95°C 
177 for 10 minutes, followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 minute for annealing and 
178 extension.  At the end of each cycle the plate was read and fluorescence intensity recorded.
179 The efficiency and optimization of the qRT-PCR reaction was evaluated by generating standard curves for 
180 three selected reference genes and target genes using a 10-fold dilution of a cDNA template. Each dilution 
181 was assayed in triplicate. PCR was carried out on a Chromo 4TM System (BioRad, UK). 
182 Western blot (WB) for AKR1C3 and CYP17A1 proteins  
183 Western immunoblot analysis of AKR1C3 and CYP17A1 protein expression in non-PCOS (n=7) and 
184 PCOS (n=4) patients was carried out by extracting total proteins from frozen SAT samples as previously 
185 described (Cadagan et al. 2014). Proteins were electrophoresed on 12% SDS-PAGE and transferred to 
186 nitrocellulose membranes by electroblotting. Following blocking with 5% Marvel in TBS, immune 
187 detection of AKR1C3 and CYP17A1 proteins was performed by incubating overnight with rabbit anti-
188 human AKR1C3 polyclonal antibodies (Antibody Registry ID, AB_2753336) a 1:1000 dilution or 
189 CYP17A1 (ID, AB_1603486), at a 1:100 dilution. After further washing, goat anti-rabbit IgG secondary 
190 antibody conjugated with alkaline phosphatase was added to blots that were left to incubate at room 
191 temperature for two hours with gentle rocking. Molecular weight markers were used to facilitate protein 
192 size detection. Visualisation of bands was carried out using Immunstar reagent (BioRad, UK) and 
193 Chemidoc V4.2 (BioRad, UK). Each blot was then stripped and re-probed using β-actin to control for 
194 loading of the protein. Protein was quantified by densitometry and relative expression levels adjusted for 
195 -actin.
196 Data analysis 
197 qRT-PCR data were expressed as comparative threshold (Ct) values and analysed using GenEx software. 
198 The mean delta Ct (ΔCt) was calculated by using the Ct method to compare the relative amount of the 
199 target sequence to the values of the chosen reference genes (Vandesompele et al. 2002). The two-tailed, 
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9200 unpaired t-test was used to compare expression levels of target genes in SAT of PCOS and non-PCOS 
201 groups. 
202 For ELISA data, values obtained were interpolated against the standard curve to determine the 
203 testosterone concentration. Students Unpaired t-test was used to compare between the PCOS and non-
204 PCOS groups. Comparison of multiple means was performed using one-way analysis of variance 
205 (ANOVA) with post hoc comparisons employing Tukey’s test. Statistical significance was considered 
206 when P<0.05. Data are expressed as mean ± SEM.
207 Results 
208 Table 1 shows characteristics of the study participants inclining PCOS women (n=15) and age- and BMI-
209 matched healthy controls (n=15).  
210 Reference genes 
211 Of the reference genes tested, GAPDH, ACTB, and LPR10 were consistently expressed and stable across 
212 PCOS and non-PCOS groups with no statistically significant (P>0.05) difference between the two groups. 
213 CYP17A1 and AKR1C3 mRNA expression in SAT 
214 CYP17A1 and AKR1C3 mRNA were expressed in SAT of both non-PCOS (n=8) and PCOS (n=8) women 
215 (Figure 1). ACTB, GAPDH, and LPR10 were the references genes used to normalise gene analysis. Data 
216 analysis showed no statistically significant (P>0.05) difference in CYP17A1 mRNA in PCOS 
217 (12.25±4.31) versus non-PCOS (8.40±4.53) SAT (Figure 1a). On the other hand, AKR1C3 mRNA 
218 expression in PCOS SAT (15.12±2.00) was significantly (P<0.001) higher than that (3.30±1.03) of the 
219 non-PCOS SAT (Figure 1b). 
220 AKR1C3 & CYP17A1 protein expression in SAT 
221 Western immunoblotting showed expression at 36kDa and 57kDa suggestive of the presence of AKR1C3 
222 and CYP17A1 respectively in SAT of both groups (non-PCOS, n=7; PCOS, n=4) (Figure 1c,d). The 
223 relative intensity (normalized to -actin) of AKR1C3 and CYP17A1 proteins expression were similar in 
Page 9 of 28 Accepted Manuscript published as JOE-18-0674.R1. Accepted for publication: 25-Feb-2019
Copyright © 2019 Society for Endocrinology Downloaded from Bioscientifica.com at 03/06/2019 08:42:26PM
via University of Nottingham
10
224 PCOS compared to non-PCOS. There was no significant difference in the protein expression between non-
225 PCOS and PCOS (AKR1C3, P=0.6989; CYP17A1, P>0.05) (Figures 1e,f). 
226
227 CYP17A1 mRNA expression in in-vitro differentiated mature adipocytes
228 Figure 2 shows CYP17A1 mRNA expression in untreated and hormone-treated mature adipocyte cultures 
229 prepared from SAT of PCOS (n=5) vs. non-PCOS (n=5) women. The expression in untreated adipocytes 
230 was significantly (P<0.0001) higher in PCOS (17.98±1.30) versus non-PCOS (1.12±0.17) adipocytes 
231 (Figure 2). Addition of increasing concentrations of insulin (1, 10, and 100nM) to the adipocyte cultures 
232 did not result in any statistically significant (P>0.05) change in the CYP17A1 mRNA expression in either 
233 of the two groups (Figure 2a). On the other hand, addition of LH (10nmol/L) resulted in a statistically 
234 significant (P<0.001) increase in CYP17A1 mRNA expression in non-PCOS, but not in PCOS adipocytes 
235 (Figure 2b). Adding increasing concentrations of insulin with LH did not have any additional effect on the 
236 expression of CYP17A1 mRNA in either of the two groups (Figure 2b).
237 AKR1C3 mRNA expression in in-vitro differentiated mature adipocytes
238 Figure 3 shows AKR1C3 mRNA expressions in untreated and hormone-treated mature adipocytes. The 
239 level in untreated mature adipocytes of PCOS women (5.19±) was significantly (P=0.01) higher than 
240 that (0.97±0.21) of non-PCOS women (Figure 3). Only insulin at 100nM resulted in a statistically 
241 significant (P<0.001) increase in the expression of AKR1C3 mRNA in adipocytes of non-PCOS, but not of 
242 PCOS women (Figure 3a). With regards to the lower insulin concentrations, there was a trend towards a 
243 dose-dependent rise in AKR1C3 mRNA expression in non-PCOS adipocytes, but this did not reach 
244 statistical significance. Addition of LH (10nmol/L) resulted a significant (P<0.01) increase in AKR1C3 
245 mRNA expression in adipocytes of non-PCOS, but not of PCOS women (Figure 3b). Adding increasing 
246 concentrations of insulin with LH, did not have any additional effect on the expression of AKR1C3 mRNA 
247 in either of the two groups. 
Page 10 of 28Accepted Manuscript published as JOE-18-0674.R1. Accepted for publication: 25-Feb-2019
Copyright © 2019 Society for Endocrinology Downloaded from Bioscientifica.com at 03/06/2019 08:42:26PM
via University of Nottingham
11
248 Testosterone concentration in differentiated adipocytes
249 Testosterone concentration in the supernatant of untreated cultured PCOS adipocytes (mean±SEM, 
250 129.27±2.54 pg/ml) was significantly (P<0.0001) higher than that (33.67±4.56 pg/ml) of non-PCOS 
251 adipocytes (Figure 4). Addition of insulin (1, 10 and 100nM) resulted in a significant dose-dependent 
252 increase in testosterone concentrations in non-PCOS adipocyte cultures but had no effect on PCOS 
253 adipocytes (Figure 4a). Adding LH (10nm/ml) to cultured adipocytes had a much more potent effect than 
254 insulin with a significant (P<0.0001) increase in testosterone concentration from adipocytes of non-PCOS 
255 women (n=5) but had no effect in PCOS adipocytes (Figure 4b). Addition of increasing insulin 
256 concentrations to LH had no additional effect on testosterone concentrations.
257 The Role of PI3-K in insulin-induce augmentation of AKR1C3 and testosterone in non-PCOS adipocytes 
258 Addition of the PI-3K inhibitor (LY294002, m/ml) with increasing concentrations of insulin to cultured 
259 non-PCOS adipocytes did not inhibit the stimulatory effect of insulin on AKR1C3 mRNA expression or 
260 testosterone concentration in adipocyte culture (Figure 5a, 5b). 
261 Discussion
262 In this in-vitro study we investigated the dynamics of androgen production and its interactions with insulin 
263 and LH in SAT biopsies obtained from women with and without PCOS. To the best of our knowledge, 
264 this is the first report on CYP17 expression, insulin actions on CYP17 and AKR1C3 and the role of the PI-
265 3k insulin signalling pathway in adipocytes derived from SAT of PCOS women. The results show 
266 upregulated AKR1C3 and CYP171A mRNA expression in SAT and in cultured subcutaneous adipocytes of 
267 PCOS women. In addition, testosterone concentrations were markedly higher in cultured adipocytes 
268 derived from SAT of PCOS women. Whilst, exposure to insulin had no effect on CYP17A1 mRNA 
269 expression, it resulted in a dose-dependent augmentation of AKRC13 expression and testosterone secretion 
270 in cultured non-PCOS adipocytes, with no effect on PCOS cultured adipocytes. These stimulatory effects 
271 of insulin are independent of the PI-3k signalling pathway. Notably, LH alone resulted in a marked 
272 increase of CYP17A1, AKR1C3 and testosterone levels in non-PCOS, but not in PCOS adipocytes.   
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273 In our experiments, we used insulin concentrations of 1, 10 and 100nM, which are equivalent to 5.7, 
274 57.3 and 573.4 ng/mL respectively. These concentrations correspond to physiological (1-30 ng/mL), 
275 moderately supraphysiological (50-100 ng/mL) and markedly supraphysiological (500-1000ng/ml) 
276 in-vivo insulin levels (Poretsky et al. 2001; Munir et al. 2004). The moderately supraphysiological 
277 levels represent insulin concentrations in women with PCOS. With regards to the LH concentration, 
278 in the absence of any previous similar studies, we used 10nmol/l, which is thought to mimic in-vivo 
279 physiological levels. However, our LH experiment should be considered preliminary and future 
280 studies should use more accurately measured concentrations to represent in-vivo physiological and 
281 supraphysiological levels.
282 As stated above, there are no previous studies on CYP17 mRNA expression in SAT of PCOS women. Our 
283 data are consistent with previous studies on non-PCOS SAT confirming the presence of CYP17 either 
284 directly by measuring CYP17 mRNA using qRT-PCR (Puche et al, 2002) or liquid chromatography-
285 tandem mass spectrometry (LC-MS/MS) (Kinoshita et al, 2014) or indirectly by measuring 17-OH-
286 Progesterone and A-dione, which require CYP17. In contrast, other studies failed to detect CYP17 mRNA 
287 in SAT of healthy women (Wang et al, 2012; Dalla Valle et al, 2006; Mackenzie et al, 2008). This may be 
288 due to an undetectable CYP17 isozyme or instability of CYP17 in adipose tissue (Kinoshita et al, 2014). 
289 Our SAT AKR1C3 data are consistent with two recent similar studies reporting increased AKR1C3 mRNA 
290 expression, measured by qRT-RT in SAT biopsies from PCOS women compared with healthy controls 
291 (O’Reilly el al, 2017; Wang et al, 2012). 
292 Our testosterone results are supported by a previous in-vivo study by O'Reilly et al (2017) who reported 
293 increased testosterone concentrations in SAT microdialysate in PCOS women (n=10) compared to healthy 
294 controls (n=10). 
295 We present the first study on the effects of insulin on AKR1C3 and CYP17A1 expression in PCOS cultured 
296 adipocytes derived from SAT. Our non-PCOS data are consistent with that of O'Reilly et al (2017) who 
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297 confirmed the stimulatory effect of insulin (20nM) on the expression and activity of AKR1C3 and 
298 CYP17A1 mRNA in cultured subcutaneous adipocytes from non-PCOS women (n=3). 
299 With regards to our PI-3k data, there have been no previous studies on adipocytes. When compared with 
300 data from the ovary, our results are consistent with one study showing that insulin-mediated 
301 steroidogenesis in granulosa cell culture was not inhibited by PI-3k inhibitor (wortmannin) (Poretsky et al. 
302 2001). In contrast, our data disagree with another study on theca cells suggesting PI-3k as a possible 
303 mediator for the insulin stimulatory effects on CYP17 mRNA expression or activity (Munir et al. 2004). 
304 Further studies are therefore required to address this uncertainty.
305 We present the first data on insulin/LH interactions in adipose tissue. Our findings are consistent with one 
306 study on theca cells showing that insulin alone is capable of stimulating testosterone production in women 
307 with and without PCOS (Nestler et al.1998). In contrast, our data disagree with another study on cultured 
308 theca cells reporting that insulin requires LH-induced cAMP activation to stimulate CYP17 activity 
309 (Munir et al. 2004). 
310 The lack of any stimulatory effects of insulin/LH on androgen production in PCOS adipocytes was 
311 surprising.  The exact explanation of this phenomenon remains uncertain. It is tempting to postulate that 
312 the high androgen levels in PCOS adipocytes may have reached a plateau level beyond which they cannot 
313 be augmented any further. However, our data do not support this hypothesis as insulin at high 
314 concentration (100nM) increased AKR1C3 and testosterone in non-PCOS adipocytes to levels higher than 
315 those of PCOS adipocytes. This suggests that PCOS AKR1C3 and testosterone are “potentially” not at a 
316 plateau. Another possible mechanism is the presence of a defect in insulin/LH receptors in PCOS 
317 adipocytes affecting their sensitivity to insulin/LH. This is supported by previous in-vitro studies reporting 
318 post-binding defect in insulin signal transduction in PCOS adipocytes in relation to glucose uptake 
319 (Diamanti-Kandarakis and Dunaif 2012; Ciaraldi et al, 1992). This defect has been attributed to serine 
320 phosphorylation of the insulin receptor and insulin receptor substrate-1 (IRS-1) secondary to increased 
321 intracellular serine kinases (Dunaif et al, 1995; Li et al, 2002; Baillargeon et al, 2007, Baptiste et al, 
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322 2010). The increase in serine kinases has also been implicated in serine phosphorylation of CYP17, which 
323 is known to increase its 17,20-lyase activity with subsequent increase in androgen production. In other 
324 words, the same serine kinase, which inhibits insulin signaling, may also increase androgen production in 
325 PCOS (Diamanti-Kandarakis and Dunaif 2012). 
326 The apparent discrepancy between the levels of mRNA and protein expressions of AKR1C3 and 
327 CYP17A1 in PCOS versus non-PCOS SAT could be due to the small numbers included in the WB 
328 experiment. Another possible explanation of the lack of mRNA-protein correlation could be due to the 
329 highly variable protein half-life ranging from  a few seconds to several days possibly due to variation in 
330 protein stability or post-translational processing as well as RNA-silencing mechanisms (Beyer et al, 2004; 
331 Wu et al, 2008; Maier et al. 2009; Greenbaum et al. 2003).
332 One limitation of our study is the lack of sufficient data on the protein expression of the androgen 
333 synthesizing enzymes in SAT.  Furthermore, we did not assess if the increased testosterone production in 
334 PCOS subcutaneous adipocyte culture is directly linked to AKR1C or CYP17A1 activity. However, 
335 evidence for this link has been provided by O’Reilly et al (2017) who reported that inhibition of AKR1C3 
336 activity by 3-4-trifluoromethyl-phenylamino-benzoic acid resulted in reduction of testosterone generation 
337 from primary subcutaneous adipocytes obtained from healthy (non-PCOS) women. 
338 Our study has provided an important and new insight into the subcutaneous adipose tissue dynamics that 
339 may contribute to the pathogenesis and pathophysiology of PCOS. Our data support the hypothesis that 
340 SAT could be an important source of PCOS-related hyperandrogenaemia. The markedly higher 
341 testosterone levels in PCOS adipocytes seem to be independent of weight as both groups were weight-
342 matched. Our data suggest that excess androgen production in subcutaneous adipocytes is not directly 
343 caused by PCOS-related hyperinsulinaemia. We also confirm that insulin and LH can each independently 
344 stimulate SAT androgen production in healthy women and there is no synergism between them. 
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345 In conclusion, subcutaneous adipose tissue of PCOS women produces increased amounts of androgen, 
346 which is not directly linked to inulin or LH. This suggests that SAT is an important contributor to the 
347 PCOS-related hyperandrogenaemia. 
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Figure legends
Figure 1. CYP17A1 and AKR1C3 in SAT of PCOS vs non-PCOS women. a & b) Relative mRNA 
expression of CYP17A1 an AKR1C3 in SAT from non-PCOS (n=8) versus PCOS (n=8) women. Data 
expressed as mean±SEM, analysed with GenEx and compared using the ΔCt method. c - f) Western 
immunoblot analysis of AKR1C3 and CYP17A1 protein expression in SAT from non-PCOS (n=7) 
versus PCOS (n=4) women. C & d) Relative intensity of AKR1C3 and CYP17A1 protein expression. 
e & f) Relative levels of band intensity in WB of AKR1C3 in both groups. Data presented as 
mean±SEM. ***P<0.001
Abbreviations: P, PCOS; Non-P, Non-PCOS; SAT, subcutaneous adipose tissue
Figure 2. CYP17A1 mRNA expression in untreated and hormone treated mature adipocyte cultures of 
PCOS (n=5) vs. non-PCOS (n=5) women.  a) Expression in adipocytes treated with different 
concentrations of insulin (1, 10, 100nM). b) Expression levels in adipocytes treated with LH (10 
nmol/ml) ± different concentrations of insulin (1 nM, 10 nM, 100 nM). Data presented as mean ± 
SEM ΔCt and analysed using one-way ANOVA. 
Data presented as mean ± SEM. ***P<0.001; ****P <0.0001
Figure 3. AKRC13 mRNA expression in untreated and hormone treated mature adipocytes of PCOS 
(n=5) vs. non-PCOS (n=5) women. a) Expression in adipocytes treated with different concentrations 
of insulin (1, 10, 100nM). b) Expression levels in adipocytes treated with LH (10nmol/ml) ± 
different concentrations of insulin (1, 10, 100nM). Data presented as mean ±SEM ΔCt and analysed 
using one-way ANOVA test. *P<0.05; **P <0.01; ***P <0.001.
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Figure 4. Testosterone secretion (pg/ml) by untreated and hormone treated mature 
adipocytes of PCOS (n=5) vs. non-PCOS (n=5) women. a) Levels in adipocytes treated with 
increasing concentrations of insulin (1, 10, 100nM). c) Levels in adipocytes treated with LH 
(10nmol/ml) ± insulin in different concentrations. Data presented as mean ± SEM and analysed 
using one-way ANOVA. **P<0.01; ***P <0.001; ****P <0.0001.
Figure 5. the role of PI-3K inhibitor (LY294002) in insulin mediated actions in non-PCOS adipocytes 
(n=5).  a) Expression of AKR1C3 in non-PCOS adipocytes treated with insulin (1, 10, 100nM) ± 
LY294002 (1g/ml). b) Testosterone levels (pg/ml) in adipocytes treated with insulin (1, 10, 100nM) 
± LY294002. Data presented as mean ± SEM and analysed using one-way ANOVA. **P<0.01; ***P 
<0.001.
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Table 1 Demography of all women included
Data summarised as median (range) and mean± SEM. 
Parameter non-PCOS(n=15)
PCOS
(n=15)
P 
value
Age (year) 32.4 (25-45) 30.5 (24-36) NS
BMI (Kg/m2) 27.5 (20.0-32.2) 29.4 (20.9-31.62) NS
Testosterone (nmol/l) 1.5 ± 0.2 2.4± 0.5 0.03
LH (nmol/l) 7.8 ± 1.4 29.8 ± 19.2 <0.01
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 Figure 1. CYP17A1 and AKR1C3 in SAT of PCOS vs non-PCOS women. a & b) Relative mRNA expression of 
CYP17A1 an AKR1C3 in SAT from non-PCOS (n=8) versus PCOS (n=8) women. Data expressed as 
mean±SEM, analysed with GenEx and compared using the ΔCt method. c - f) Western immunoblot analysis 
of AKR1C3 and CYP17A1 protein expression in SAT from non-PCOS (n=7) versus PCOS (n=4) women. C & 
d) Relative intensity of AKR1C3 and CYP17A1 protein expression. e & f) Relative levels of band intensity in 
WB of AKR1C3 in both groups. Data presented as mean±SEM. ***P<0.001 
Abbreviations: P, PCOS; Non-P, Non-PCOS; SAT, subcutaneous adipose tissue 
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 Figure 2. CYP17A1 mRNA expression in untreated and hormone treated mature adipocyte cultures of PCOS 
(n=5) vs. non-PCOS (n=5) women.  a) Expression in adipocytes treated with different concentrations of 
insulin (1, 10, 100nM). b) Expression levels in adipocytes treated with LH (10 nmol/ml) ± different 
concentrations of insulin (1 nM, 10 nM, 100 nM). Data presented as mean ± SEM ΔCt and analysed using 
one-way ANOVA. 
Data presented as mean ± SEM. ***P<0.001; ****P <0.0001
230x198mm (266 x 266 DPI) 
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 Figure 3. AKRC13 mRNA expression in untreated and hormone treated mature adipocytes of PCOS (n=5) vs. 
non-PCOS (n=5) women. a) Expression in adipocytes treated with different concentrations of insulin (1, 10, 
100nM). b) Expression levels in adipocytes treated with LH (10nmol/ml) ± different concentrations of insulin 
(1, 10, 100nM). Data presented as mean ±SEM ΔCt and analysed using one-way ANOVA test. *P<0.05; **P 
<0.01; ***P <0.001. 
522x399mm (120 x 120 DPI) 
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 Figure 4. Testosterone secretion (pg/ml) by untreated and hormone treated mature adipocytes of PCOS 
(n=5) vs. non-PCOS (n=5) women. a) Levels in adipocytes treated with increasing concentrations of insulin 
(1, 10, 100nM). c) Levels in adipocytes treated with LH (10nmol/ml) ± insulin in different concentrations. 
Data presented as mean ± SEM and analysed using one-way ANOVA. **P<0.01; ***P <0.001; ****P 
<0.0001. 
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 Figure 5. the role of PI-3K inhibitor (LY294002) in insulin mediated actions in non-PCOS adipocytes (n=5). 
 a) Expression of AKR1C3 in non-PCOS adipocytes treated with insulin (1, 10, 100nM) ± LY294002 
(1g/ml). b) Testosterone levels (pg/ml) in adipocytes treated with insulin (1, 10, 100nM) ± LY294002. 
Data presented as mean ± SEM and analysed using one-way ANOVA. **P<0.01; ***P <0.001. 
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